Literature DB >> 12746565

Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.

Beatriz González-Yebra1, María Elena Medrano, Alejandra Mantilla, Virginia Palma, Carmen Colin, Dulce María Hernández, José Tapia, Brian Dawson, Mauricio Salcedo.   

Abstract

Multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC) are characterized by development of medullary thyroid carcinoma (MTC) and caused by germline RET mutations. Patients with MEN 2A also develop pheochromocytoma and/or hyperparathyroidism (HPT). However, MEN 2A-affected individuals could display the FMTC phenotype at first clinical manifestation. To establish the correct phenotype and improve clinical management of patients affected by hereditary MTC, clinical screening, RET mutational analysis, penetrance of MTC, and genotype-phenotype correlation were performed in a large, suspected FMTC kindred of 86 individuals. Germline C634Y RET mutation was confirmed in 22 individuals, 15 of whom were thyroidectomized when high serum calcitonin levels were detected. MTC was confirmed in 12 individuals and C-cell hyperplasia in 3. HPT was detected in two patients. High penetrance of MTC at young age (79% at 30 yr of age) was found. This family was considered to be affected by FMTC for several years because MTC was the sole clinical manifestation. However, our results allowed reclassifying the family as MEN 2A, thereby improving clinical management of family members. Our findings regarding penetrance and genotype-phenotype correlation suggest that patients considered to have FMTC may in fact have MEN 2A in some kindreds.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746565     DOI: 10.1385/ep:14:1:71

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  34 in total

1.  Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine.

Authors:  I Schuffenecker; M Virally-Monod; R Brohet; D Goldgar; B Conte-Devolx; L Leclerc; O Chabre; A Boneu; J Caron; C Houdent; E Modigliani; V Rohmer; M Schlumberger; C Eng; P J Guillausseau; G M Lenoir
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

2.  Alcohol-stimulated calcitonin release in medullary carcinoma of the thyroid.

Authors:  S L Cohen; I MacIntyre; D Grahame-Smith; J G Walker
Journal:  Lancet       Date:  1973-11-24       Impact factor: 79.321

3.  Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.

Authors:  A M Moers; R M Landsvater; C Schaap; J M Jansen-Schillhorn van Veen; I A de Valk; G H Blijham; J W Höppener; T M Vroom; H K van Amstel; C J Lips
Journal:  Am J Med       Date:  1996-12       Impact factor: 4.965

4.  Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy.

Authors:  H Siggelkow; A Melzer; W Nolte; K Karsten; W Hoppner; M Hufner
Journal:  Eur J Endocrinol       Date:  2001-05       Impact factor: 6.664

5.  Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A.

Authors:  R F Gagel; G J Cote; M J Martins Bugalho; A E Boyd; T Cummings; H Goepfert; D B Evans; A Cangir; S Khorana; P N Schultz
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

6.  Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium.

Authors:  L M Mulligan; D J Marsh; B G Robinson; I Schuffenecker; J Zedenius; C J Lips; R F Gagel; S I Takai; W W Noll; M Fink
Journal:  J Intern Med       Date:  1995-10       Impact factor: 8.989

7.  Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma.

Authors:  H J Karga; M K Karayianni; D A Linos; S C Tseleni; K D Karaiskos; P D Papapetrou
Journal:  Eur J Endocrinol       Date:  1998-10       Impact factor: 6.664

8.  Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A.

Authors:  S A Wells; D D Chi; K Toshima; L P Dehner; C M Coffin; S B Dowton; J L Ivanovich; M K DeBenedetti; W G Dilley; J F Moley
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

Review 9.  Current perspectives on the diagnosis and management of patients with multiple endocrine neoplasia type 2 syndromes.

Authors:  S A Wells; H Donis-Keller
Journal:  Endocrinol Metab Clin North Am       Date:  1994-03       Impact factor: 4.741

10.  Genetics. One gene--four syndromes.

Authors:  V van Heyningen
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962

View more
  1 in total

1.  Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634.

Authors:  Oliver Gimm; Jörg Ukkat; Barbara E Niederle; Theresa Weber; Phuong Nguyen Thanh; Michael Brauckhoff; Bruno Niederle; Henning Dralle
Journal:  World J Surg       Date:  2004-11-04       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.